ArticleMucosal immunology2013
Th17 responses in chronic allergic airway inflammation abrogate regulatory T-cell-mediated tolerance and contribute to airway remodeling.
Article in Mucosal immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 216 citations in OpenAlex.
- Acanthamoeba profilin as a novel airway allergen with diverse sensitization patterns including pollen cross-reactivity.Parasites, hosts and diseases · 2026Article
- Article
- Fusing data from CT deep learning, CT radiomics and peripheral blood immune profiles to diagnose lung cancer in a cohort of patients experiencing symptoms.EBioMedicine · 2026Article
- Hem1 controls T cell activation, memory, and the regulated release of immunosuppressive and proinflammatory cytokines.JCI insight · 2025Article
- Unmasking Pediatric Asthma: Epigenetic Fingerprints and Markers of Respiratory Infections.International journal of molecular sciences · 2025Review
- Urban Lifestyle and Climate-Driven Environmental Exposures: Immunological Consequences for Pediatric Respiratory Allergies.Immunity, inflammation and disease · 2025Review
- Targeted Biologic Therapies in Severe Asthma: Mechanisms, Biomarkers, and Clinical Applications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Lung CD4Cell reports · 2025Article
- Therapeutic potency and possible mechanism of Wuhu decoction underlying asthmatic progression via Th1/Th2 imbalance.Journal of thoracic disease · 2025Article
- Ferroptosis-immune-metabolic axis in asthma: mechanistic crosstalk, endotype-specific regulation, and translational targeting.Frontiers in immunology · 2025Review
- The role of T-helper and T regulatory cells in driving neutrophilic and eosinophilic inflammation in bronchiectasis.Frontiers in immunology · 2025Review
- Ion Channels in the Immune Response of Asthma.Journal of respiratory biology and translational medicine · 2024Article
- Retinoic Acid (RA): A Critical Immunoregulatory Molecule in Asthma and Allergies.Immunity, inflammation and disease · 2024Review
- Targeting Common Inflammatory Mediators in Experimental Severe Asthma and Acute Lung Injury.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Immunologic aspects of asthma: from molecular mechanisms to disease pathophysiology and clinical translation.Frontiers in immunology · 2024Review
- Cytotoxic CD4Med (New York, N.Y.) · 2023Article
- Review
- T helper 2 cells in asthma.The Journal of experimental medicine · 2023Review
- Lipid Mediators Metabolic Chaos of Asthmatic Mice Reversed by Rosmarinic Acid.Molecules (Basel, Switzerland) · 2023Article
- Editorial: Bridging the gap between immunology, virology, genetics, and epigenetics in bronchiolitis: The multiomics pathway to asthma development.Frontiers in immunology · 2023Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The role of T-helper type 17 (Th17) responses in airway remodeling in asthma is currently unknown. We demonstrate that both parenteral and mucosal allergen sensitization, followed by allergen inhalation, leads to Th17-biased lung immune responses. Unlike Th17 cells generated in vitro, lung Th17 cells did not produce tumor necrosis factor-α or interleukin (IL)-22. Eosinophilia predominated in acute inflammation, while neutrophilia and IL-17 increased in chronic disease. Allergen-induced tolerance involved Foxp3-, Helios-, and glycoprotein-A repetitions predominant-expressing regulatory T cells (Treg) and IL-10/interferon-γ priming. This Treg phenotype was altered in inflamed lungs and abrogated by inhalation of IL-17. Using Th17-deficient mice with genetic disruption of gp130 in T cells, we showed that Th17 cells induce airway remodeling independent of the Th2 response. All-trans retinoic acid administration ameliorated Th17-mediated disease and increased Treg activity, while dexamethasone inhibited eosinophilia but not neutrophilia, and enhanced Th17 development in vitro. Targeting the Th17/Treg axis might therefore be therapeutic in neutrophilic and glucocorticoid-refractory asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.